Cancer Vaccine Week articles from June 2009

Cancer Vaccine Week archives from June 2009

Stanford University reports research in cancer vaccines.
June 1, 2009... "We have previously shown that intratumoral injection of CpG oligodeoxynucleotide plus systemic chemotherapy can induce a T-cell immune response against lymphoma and serve as a therapeutic vaccine to cure tumors in a murine model. Here, we...

Scientists at University of Charleston discuss research in human papillomavirus.
June 1, 2009... According to recent research published in the journal Annals of Pharmacotherapy, "The human papillomavirus (HPV) quadrivalent vaccine was licensed in 2006 for prevention of cervical, vulvar, and vaginal cancers caused by HPV-16 and -18 and...

Scientists at University of Tubingen target immunization.
June 1, 2009... According to a study from Tubingen, Germany, "Experimental tumor vaccination and adoptive T-cell therapies show that interferon-gamma (IFN-gamma)-producing CD4(+) T helper cells (Th1) can be highly effective in tumor prevention and therapy....

Research reports on Newcastle disease from C. Pfirschke and colleagues provide new insights.
June 1, 2009... According to a study from Heidelberg, Germany, "Oncolytic virotherapy, a new type of cancer therapy involving viruses with oncolytic and immunostimulatory potential, is based on tumor selective viral replication, resulting in a specific lysis...

Disruption of Immune-System Pathway Key Step in Cancer Progression, Stanford Study Shows.
June 1, 2009... Human immune cells communicate constantly with one another as they coordinate to fight off infection and other threats. Now researchers at Stanford University's School of Medicine have shown that muffling a key voice in this conversational...

Center of Molecular Immunology details research in cancer vaccines.
June 1, 2009... A report, 'Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma,' is newly published data in Cancer Immunology, Immunotherapy. "Anti-idiotype...

New findings from A.M. Asemissen and co-authors in the area of cancer vaccines published.
June 1, 2009... Scientists discuss in 'Vaccination strategies in patients with renal cell carcinoma' new findings in cancer. "Although new treatment options for patients with advanced renal cell cancer (RCC) have been developed within recent years, vaccination...

New findings in cancer vaccines described by M. Iero and co-researchers.(Clinical report)
June 1, 2009... New investigation results, 'Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity,' are detailed in a study published in Cancer Immunology, Immunotherapy. According to a study from Milan, Italy, "The...

Scientists at Innsbruck Medical University describe research in cancer vaccines.
June 1, 2009... Research findings, 'Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy,' are discussed in a new report. "Langerhans cells, a subset of skin dendritic cells in the epidermis,...

Scientists at St. George's University, Department of Oncology report research in cancer vaccines therapy.
June 1, 2009... A new study, 'The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells,' is now available. "Lenalidomide (Revlimid; CC-5013) and pomalidomide (CC-4047) are IMiDs proprietary drugs having...

Research reports from Karolinska Institute Cancer Center provide new insights into vaccines.(Report)
June 1, 2009... Research findings, 'Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production,' are discussed in a new report. According to recent research from Stockholm, Sweden, "We...

Pharma and Biotech Companies Plug into Singapore's Integrated Research Network.
June 1, 2009... Leading pharmaceutical and biotech companies are drawing on Singapore's integrated network of public-sector and academic institutes to enhance their R&D productivity, leverage academic insights and diversify risks. Located at the heart of Asia...

The Diagnosis Every Woman Dreads - Ovarian Cancer.
June 1, 2009... As a health care practitioner, Trina Hammack knew the statistics. So when she was diagnosed with ovarian cancer, she knew her prognosis was bleak. Fortunately, Hammack was familiar with a clinic in Mexico offering effective new treatments for...

Wellmark Leverages MDdatacor Technology to Streamline Immunization Tracking.
June 1, 2009... MDdatacor, Inc., a leader in health care quality management solutions for insurers and health care providers, announced new functionality to support in tracking immunizations to further enhance the Collaboration on Quality(R) Primary Care...

Pfizer to Present New Clinical Data Highlighting Customized Treatment Approaches for Difficult-To-Treat Cancers.
June 1, 2009... Pfizer will present new data highlighting the company's commitment to a personalized approach to oncology clinical research, which includes the use of targeted agents in specific patient populations in several advanced and difficult-to-treat...

Investigational Drug Shows Promise as Treatment for Overexposure to Common Cancer Chemotherapy.
June 1, 2009... The emergency use of an investigational drug has yielded promising results in reducing the potentially fatal side effects of the widely used cancer chemotherapy 5-fluorouracil (5-FU), according to clinical data that will be reported June 1 at...

New broad-spectrum vaccine to prevent cervical cancer induces strong responses in animals.
June 8, 2009... Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus (HPV) type 16 four months after vaccination, according to a new study published...

Protein predicts development of invasive breast cancer in women with DCIS, Penn study shows.
June 8, 2009... Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer, according to a new study from the University of Pennsylvania School of Medicine. The...

Reports from Army advance knowledge in cancer vaccines.
June 8, 2009... "HER2/neu, a source of immunogenic peptides, is expressed in > 75% of breast cancer patients. We have conducted clinical trials with the HER2/neu E75 peptide vaccine in breast cancer patients with varying levels of HER2/neu expression,"...

Research conducted at N. Thiry and co-authors has provided new information about cancer vaccines.
June 8, 2009... "The cost-effectiveness of adding a human papillomavirus (HPV) vaccination program in 12-year-old females to the recommended cervical cancer screening in Belgium is examined. Moreover, the health and economic consequences of a potential decline...

Research from Harvard University in the area of cancer vaccines described.
June 8, 2009... According to a study from the United States, "Interferon (IFN) is effective at inducing complete remissions in patients with chronic myelogenous leukemia (CML), and evidence supports an immune mechanism." "Here we show that the type I IFNs...

Advaxis Applies for $2.0 Million U.S. Bio-Defense Grant.
June 8, 2009... Advaxis, Inc. (OTCBB: ADXS) has applied for a $2 million biodefense grant, in collaboration with a healthcare company (Collaborator), to develop an oral formulation of its live Listeria technology for the prevention of influenza (see also...

Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights.
June 8, 2009... The US Patent and Trademark office approved Advaxis Incorporated (OTCBB: ADXS) patent-application Compositions and Methods for Enhancing the Immunogenicity of Antigens (Application # US2005/0118184 A1). This patent application covers the use of...

Personalized Anti-Cancer Vaccine Pivotal Phase III Results to be Presented at ASCO Plenary Session.
June 8, 2009... Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), announced that BiovaxID®, Biovest's personalized anti-cancer vaccine targeting B-cell blood cancers, will be...

Invitation: PROSTVAC(TM) Wrap up.
June 8, 2009... Following the presentation of data with PROSTVAC(TM) - a promising, late-stage vaccine candidate for the treatment of advanced prostate cancer, Bavarian Nordic will be hosting a Q&A session at the ASCO Annual Meeting (see also Cancer Vaccines)....

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide.
June 8, 2009... PAREXEL International Corporation (NASDAQ:PRXL), a leading global biopharmaceutical services provider, announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000...

Sexually Transmitted HPV Linked to Certain Head & Neck Cancers.
June 8, 2009... Researchers at Roswell Park Cancer Institute (RPCI) in Buffalo, New York, are strongly advocating a national discussion about the need to vaccinate both young men and women against HPV 16 to prevent head & neck cancers. The call comes amid...

GARDASIL[R] is First Cervical Cancer Vaccine to Receive WHO Pre-qualification.
June 8, 2009... GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine...

Cancer Drug Discoveries: What the Future Holds for the Non-Small Cell Lung Cancer Market and Therapeutic Approaches.
June 8, 2009... Research and Markets (http://www.researchandmarkets.com/research/cf404c/cancer_drug_discov) has announced the addition of the "Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter" report to their offering (see...

Common diabetes drug may 'revolutionize' cancer therapies.
June 15, 2009... This release is available in French (see also McGill University). Researchers at McGill University and the University of Pennsylvania have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency...

Data from St. Louis University provide new insights into cancer vaccines.
June 15, 2009... According to a study from the United States, "Chronic infection with the hepatitis B virus has been linked epidemiologically to the development of hepatocellular carcinoma for more than 30 years. Although the mechanisms by which chronic...

Findings from Westmead Hospital broaden understanding of cancer vaccines.
June 15, 2009... "The risk of cervical cancer in women who are kidney transplant recipients is increased, but little is known about the effectiveness of screening and human papillomavirus (HPV) vaccination in this group of women. We sought to determine the cost...

Reports summarize cancer vaccines research from F.X. Ding and co-authors.
June 15, 2009... "To develop a hepatitis B virus (HBV) therapeutic vaccine that can induce a broad but specific immune response and significant antitumor effects both in vivo and in vitro, we inserted HBV X protein (HBx)-derived epitopes HBX(52-60),...

Research from J. Bornstein and colleagues has provided new data on cancer vaccines.
June 15, 2009... According to recent research from Haifa, Israel, "This review presents an unbiased comparison between the two vaccines available against human papillomavirus (HPV). We conducted a PUBMED and Google search for the years 1998 to October 2008...

Researchers from University of Insubria discuss findings in vaccines.
June 15, 2009... New investigation results, 'Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions,' are detailed in a study...

Advaxis Develops Innovative Approach in Cancer Mechanism Targeting.
June 15, 2009... Advaxis Incorporated (OTCBB:ADXS) has developed an innovative approach in targeting cancer that enables a single bioengineered Listeria monocytogenes (Lm) bacterium to simultaneously secrete two different antigen-adjuvant fusion proteins (see...

Antigenics Presents Positive Oncophage[R] Interim Survival Data at ASCO.
June 15, 2009... Antigenics Inc. (NASDAQ: AGEN) announced results of an interim analysis from the company's ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an...

Pfizer and Celldex Therapeutics Present Update on CDX-110 PF-04948568 Phase 2 Brain Cancer Studies at 45th Annual ASCO Meeting.
June 15, 2009... Pfizer (NYSE: PFE) and Celldex Therapeutics (NASDAQ: CLDX) announced the presentation of updated data from two clinical trials of CDX-110 in newly-diagnosed glioblastoma multiforme (GBM) at the 45th Annual Meeting of the American Society of...

Merck KGaA: Follow-Up From Stimuvax Study Provides Long-Term Safety Data In Advanced Lung Cancer Patients Receiving Treatment for Up To 8.2 Years.(Clinical report)
June 15, 2009... Extended follow-up safety data from a randomized Phase IIb study of patients with inoperable advanced (stage IIIb/IV) non-small cell lung cancer (NSCLC) have shown that the most common treatment-related adverse events observed in patients...

Penn study demonstrates new way to boost immune memory.(Report)
June 15, 2009... After a vaccination or an infection, the human immune system remembers to keep protecting against invaders it has already encountered, with the aid of specialized B-cells and T-cells. Immunological memory has long been the subject of intense...

Data on cancer vaccines published by researchers at National Cancer Institute.
June 22, 2009... "The tumor-associated Tn antigen has been investigated extensively as a biomarker and therapeutic target. Cancer vaccines containing the Tin antigen as a single tumor antigen or as a component of a polyvalent vaccine have progressed into phase...

New cancer vaccines study findings recently were published by researchers at University of California.
June 22, 2009... According to a study from the United States, "Whereas chemotherapy is the standard of care for metastatic castration-resistant prostate cancer and is associated with a survival benefit, there remains a need for alternative approaches. Extensive...

New findings in cancer vaccines described by J. Zeng and co-researchers.
June 22, 2009... According to a study from Guangzhou, People's Republic of China, "The present study investigated an immunotherapeutic strategy for rearranged during transfection proto-oncogene (ret)associated carcinomas in a transgenic MT/ret 304/B6 mouse...

Study results from L. Annemans and colleagues in the area of cancer vaccines published.
June 22, 2009... According to recent research from Lyon, France, "The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical intraepithelial neoplasia...

Study results from McMaster University update understanding of cancer vaccines.
June 22, 2009... According to recent research from Hamilton, Canada, "Tumors that recur following surgical resection of melanoma are typically metastatic and associated with poor prognosis. Using the murine B16F10 melanoma and a robust antimelanoma vaccine, we...

King's College London, King's College London describes research in cancer vaccines immunology.
June 22, 2009... Fresh data on cancer vaccines are presented in the report 'Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model.' According to recent research from London, the United Kingdom, "Changes in the composition of...

Advaxis CEO Thomas A. Moore Interviewed.
June 22, 2009... The Wall Street Transcript interviewed CEO Thomas A. Moore of Advaxis, Inc. (OTCBB: ADXS) where he addressed questions regarding the Company's progress and the development of its Listeria-based platform technology. For further information,...

Advaxis Receives FDA Response to Orphan Drug Filing.
June 22, 2009... Advaxis, Inc. (OTCBB:ADXS) received the FDA letter late on June 1 denying the company's request for Orphan Drug Designation (ODD) for the use of ADXS11-001 in invasive cervix cancer. The FDA stated their market definition for invasive cervical...

AMAG Pharmaceuticals Announces Appointment of Ricardo Zayas as Senior Vice President of Operations.
June 22, 2009... AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on treating iron deficiency anemia and developing novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, announced that Ricardo Zayas has...

Cancer Center Leads Breakthrough Clinical Trial: Vaccine shows promise for first time against Melanoma.(Clinical report)
June 22, 2009... A recent clinical trial - led by Goshen Center for Cancer Care - has yielded promising results for the future use of a cancer vaccine. One of the first studies to prove vaccines might have a medical benefit against cancer, study results found...

Study: Benefit to Women Not Enough to Sway Men to Get HPV Vaccine.
June 22, 2009... Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the...

Techne Corporation Board Member Recognized.
June 22, 2009... Charles A. Dinarello, M.D., a Professor of Medicine at the University of Colorado School of Medicine in Denver and a member of the Techne Corporation Board of Directors, was recently recognized with two distinguished awards (see also...

FDA Approves First Canine Cancer Therapy.
June 22, 2009... Pfizer Animal Health announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S. - PALLADIATM (toceranib phosphate) - which was developed by Pfizer to treat mast cell tumors in dogs....

U.S. Non-Infectious Disease Vaccine Pipeline - Oncology, Cardiovascular, Multiple Sclerosis, Addiction Disorders...
June 22, 2009... Research and Markets (http://www.researchandmarkets.com/research/fcc7e9/u_s_noninfectiou) has announced the addition of Frost & Sullivan's new report "U.S. Non-Infectious Disease Vaccine Pipeline" to their offering (see also Research and...